Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non Small Cell Lung Cancer Metastatic: early-phase trial registry
4 of 17 indexed Non Small Cell Lung Cancer Metastatic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 4 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Non Small Cell Lung Cancer Metastatic: 17 US clinical trials tracked, 4 recruiting.
Non Small Cell Lung Cancer Metastatic is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer-metastatic
OPEN 4 | RECR 24% | LATE 2 | EARLY 13 | RANK #1004 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Cataract (24% recruiting · 85 trials)
Non Small Cell Lung Cancer Metastatic lists 4 open slots (24% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non Small Cell Lung Cancer Metastatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non Small Cell Lung Cancer Metastatic is recruiting below its size-band peers.
4 of 17 indexed trials (23.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Non Small Cell Lung Cancer Metastatic research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 17 trials (17.6%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Non Small Cell Lung Cancer Metastatic enrolment sits around 107 participants.
Median target enrolment is 107 among the 17 trials that report a genuine target (sentinel values excluded). 8 of those (47.1%) plan for fewer than 100 participants.
-
Non Small Cell Lung Cancer Metastatic research is mostly interventional.
16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Pfizer
NCT07144280
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
NCT05657873
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
NCT06741085
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
University of California, Davis
NCT07250477
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Sophia Genetics SAS
NCT04994795
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
NCT03319628
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Sanofi
NCT04154956
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
NCT04619004
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
Charu Aggarwal
NCT05853887
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
NCT04868877
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
Genmab
NCT05117242
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
Memorial Sloan Kettering Cancer Center
NCT03808662
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03377023
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT03907852
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
University of Utah
NCT04163432
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
H. Lee Moffitt Cancer Center and Research Institute
NCT03611738
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
Mersana Therapeutics
NCT06517433
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 7 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Non Small Cell Lung Cancer Metastatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non Small Cell Lung Cancer Metastatic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non Small Cell Lung Cancer Metastatic page
17 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Non Small Cell Lung Cancer Metastatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Non Small Cell Lung Cancer Metastatic trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non Small Cell Lung Cancer Metastatic condition card totals 17 registered trials; most-linked intervention upifitamab rilsodotin; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.